Taysha Gene Therapies (TSHA) Stock Price, Quote, News & History | Benzinga

Taysha Gene Therapies Inc (TSHA) Stock Price, Quote, News & History

TSHANASDAQ

Trade with Public

Trade with Public

$6.37

-0.09-1.39%

Last update: Aug 6, 7:52 AM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$6.39

Close

-

Volume / Avg.

952.51K / 3.06M

Day Range

$6.28 - $6.55

52 Wk Range

2.63 - 7.30

Market Cap

$1.83B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

16.05%

Days to Cover

13.34

Recent Taysha Gene Therapies, Inc. News

Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Canaccord cut Strategy's target, Barclays upgraded Watts Water, Rosenblatt boosted Comcast, Goldman increased State Street, Evercore raised Owens Corning, Cantor Fitzgerald boosted BioCryst Pharma, BTIG raised Edwards Lifesciences.

Avi Kapoor

H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session

U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.

Avi Kapoor

Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket

Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3 results and issuing strong guidance. Autozi Internet Technology, Focus Universal, SAGTEC GLOBAL, Eshallgo, Eco Wave Power Global, Innovation Beverage Group, Nexera Technologies, Methode Electronics, and Wendy's Co are among the other stocks moving in pre-market trading.

Avi Kapoor

Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.

Avi Kapoor

Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-111.95M

Investing Cash Flow (TTM)

-3.26M

Financing Cash Flow (TTM)

275.35M

Free Cash Flow (TTM)

-115.33M

Capital Expenditure (TTM)

-3.38M

Net Change in Cash (TTM)

160.15M

Analyst Trends and Forecast

3

Mar

1

Apr

5

Jun

1

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.65B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

297.72

PB Ratio (TTM)

8.77

Earnings Yield % (TTM)

-5.88%

Earnings Yield % (FWD)

-7.27%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.74

Company Debt

Total Debt

$48.96M

LT Debt

$48.96M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$276.58M

Debt to Equity

0.32

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$6.39

Close

-

Volume / Avg.

952.51K / 3.06M

Day Range

$6.28 - $6.55

52 Wk Range

2.63 - 7.30

Market Cap

$1.83B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

16.05%

Days to Cover

13.34

About

Sector

Health Care

Industry

Biotechnology

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in deve...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Taysha Gene Therapies (TSHA) stock?

A

You can purchase shares of Taysha Gene Therapies (NASDAQ:TSHA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Taysha Gene Therapies (TSHA) competitors?

A

There are no as such competitors for Taysha Gene Therapies.

Q

What is the forecast, or price target, for Taysha Gene Therapies (TSHA) stock?

A

Taysha Gene Therapies has a consensus price target of $10.75.

Q

What is the current price for Taysha Gene Therapies (TSHA)?

A

The stock price for Taysha Gene Therapies (NASDAQ: TSHA) is $6.37 last updated August 6, 2026 at 7:52 AM EDT.

Q

Does Taysha Gene Therapies (TSHA) pay a dividend?

A

There are no upcoming dividends for Taysha Gene Therapies.

Q

When is Taysha Gene Therapies (NASDAQ:TSHA) reporting earnings?

A

Taysha Gene Therapies does not have any upcoming earnings scheduled.

Q

Is Taysha Gene Therapies (TSHA) going to split?

A

There is no upcoming split for Taysha Gene Therapies.

Q

What sector and industry does Taysha Gene Therapies (TSHA) operate in?

A

Taysha Gene Therapies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.